• Monash IVF received an unsolicited, conditional, and non-binding proposal from a consortium to acquire 100% of the company
• The proposed cash offer price of $0.80 per share is considered to materially undervalue the company
• The Board unanimously rejected the proposal as not being in the best interest of shareholders

Monash IVF Group Limited (ASX:MVF) has received an opportunistic, unsolicited, conditional and non-binding indicative proposal from a consortium comprising Genesis Capital Investment Management Pty Ltd and WHSP Holdings Pty Limited to acquire 100% of the shares in Monash IVF by way of a Scheme of Arrangement. The indicative cash price offered to shareholders under the Proposal is $0.80 per share. The Board has considered the Proposal, including with the assistance of its financial and legal advisers, and unanimously determined that the Proposal materially undervalues Monash IVF and is not in the best interest of the Company's shareholders as a whole. The Board has therefore determined to reject the proposal in its current form. The Board considered that the Offer Price is at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remains conditional and will require further due diligence, and there is uncertainty in respect of the financing arrangements proposed by the Consortium. The Board will act in the interests of shareholders as a whole and will consider any change of control proposals that it receives, but will only progress such a proposal if it believes it represents compelling value for Monash IVF shareholders.